Real-world experience with netakimab in the treatment of spondyloarthritis

Alexey D. Meshkov; Мешков Алексей Дмитриевич; Natalya M. Vorobyeva; Воробьева Наталья Михайловна; Valentina S. Ostapenko; Остапенко Валентина Сергеевна; Valentina S. Pykhtina; Пыхтина Валентина Сергеевна; Viktoriya I. Ruzanova; Рузанова Виктория Ивановна; Olesia A. Perlova; Перлова Олеся Андреевна; Irina S. Kordyukova; Кордюкова Ирина Сергеевна; Anton V. Naumov; Наумов Антон Вячеславович; Natalia O. Khovasova; Ховасова Наталья Олеговна; Olga N. Tkacheva; Ткачева Ольга Николаевна

doi:10.26442/00403660.2023.12.202547

Real-world experience with netakimab in the treatment of spondyloarthritis

Authors: Meshkov A.D.¹, Vorobyeva N.M.¹, Ostapenko V.S.¹, Pykhtina V.S.¹, Ruzanova V.I.¹, Perlova O.A.¹, Kordyukova I.S.¹, Naumov A.V.¹, Khovasova N.O.¹, Tkacheva O.N.¹
Affiliations:
1. Pirogov Russian National Research Medical University
Issue: Vol 95, No 12 (2023)
Pages: 1172-1178
Section: Original articles
URL: https://journals.rcsi.science/0040-3660/article/view/258745
DOI: https://doi.org/10.26442/00403660.2023.12.202547
ID: 258745

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Aim. To study the real-world efficacy and safety of netakimab in the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

Materials and methods. The retrospective analysis included 23 patients (13 males; 56.5%) aged 23 to 73 years (median 42, interquartile range 28 to 52 years) with AS (n=12) or PsA (n=11) who received netakimab therapy from February 2021 to April 2023. Disease activity was assessed every 3-6 months based on the C-reactive protein (CRP) level for all patients according to the BASDAI and ASDAS-CRP indices for AS, DAPSA and PASI for PsA. These indicators were analyzed before therapy and at the last visit to assess the effectiveness of treatment. The results are presented as median (interquartile range).

Results. In all patients treated with netakimab (median duration of treatment 11 months), the CRP level decreased from 10.6 (3.1; 17.3) to 3.1 (1.9; 8.9) mg/L (absolute difference -7.5 mg/L, median relative reduction -60%; p=0.008), and the proportion of patients with elevated CRP decreased from 70 to 41%; p=0.039. In patients with AS (median duration of treatment 9 months), BASDAI score decreased from 5.8 (4.7; 6.5) to 3.0 (1.9; 3.8) points (absolute difference -2.8 points, median relative reduction of -45%; p=0.008) and ASDAS-CRP score decreased from 2.8 (1.9; 3.9) to 1.9 (1.7; 2.6) points (absolute difference -0.9 points, median relative reduction -21%; p=0.007). The proportion of patients with high AS activity (BASDAI≥4) decreased from 90% to 20% (p=0.031); however, there was no significant change in the CRP level (absolute difference -4.9 mg/L, median relative reduction -57%; p=0.110). In patients with PsA (median duration of treatment 18 months), the CRP level decreased from 12.0 (4.5; 17.3) to 3.3 (2.0; 7.8) mg/L (absolute difference -8.7 mg/L, median relative reduction -80%; p=0.041), the DAPSA score decreased from 23.0 (19.0; 30.5) to 6.3 (5.2; 13.5) points (absolute difference -16.7 points, median relative reduction -69%; p=0.018). Three (13%) patients reported mild to moderate adverse events.

Conclusion. The obtained data confirm the effectiveness and safety of netakimab in treating AS and PsA in real-world practice.

Keywords

netakimab, interleukin-17A inhibitor, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, genetically engineered biological agents, real-world practice